The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety for trifluridine/tipiracil (TAS-102) with bevacizumab combination in patients with refractory metastatic colorectal cancer in real-world clinical practice: The single-institutional experience.
 
Kayo Yasuda
No Relationships to Disclose
 
Daisuke Kotani
No Relationships to Disclose
 
Yasutoshi Kuboki
Honoraria - Bayer; Taiho Pharmaceutical
 
Shota Fukuoka
No Relationships to Disclose
 
Hideaki Bando
Research Funding - AstraZeneca; Sysmex
 
Akihito Kawazoe
No Relationships to Disclose
 
Yoshiaki Nakamura
No Relationships to Disclose
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takayuki Yoshino
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline K.K. (Inst)